These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1047 related items for PubMed ID: 19617343

  • 21. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors.
    Frilling A, Sotiropoulos GC, Radtke A, Malago M, Bockisch A, Kuehl H, Li J, Broelsch CE.
    Ann Surg; 2010 Nov; 252(5):850-6. PubMed ID: 21037441
    [Abstract] [Full Text] [Related]

  • 22. Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours.
    Kumar R, Sharma P, Garg P, Karunanithi S, Naswa N, Sharma R, Thulkar S, Lata S, Malhotra A.
    Eur Radiol; 2011 Nov; 21(11):2408-16. PubMed ID: 21750886
    [Abstract] [Full Text] [Related]

  • 23. Impact of peptide receptor radionuclide therapy on the 68Ga-DOTATOC-PET/CT uptake in normal tissue.
    Giesel FL, Stefanova M, Schwartz LH, Afshar-Oromieh A, Eisenhut M, Haberkorn U, Kratochwil C.
    Q J Nucl Med Mol Imaging; 2013 Jun; 57(2):171-6. PubMed ID: 23370092
    [Abstract] [Full Text] [Related]

  • 24. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
    Barone R, Walrand S, Konijnenberg M, Valkema R, Kvols LK, Krenning EP, Pauwels S, Jamar F.
    Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
    [Abstract] [Full Text] [Related]

  • 25. [Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinations].
    Hartmann H, Zöphel K, Freudenberg R, Oehme L, Andreeff M, Wunderlich G, Eisenhofer G, Kotzerke J.
    Nuklearmedizin; 2009 Mar; 48(5):201-7. PubMed ID: 19639164
    [Abstract] [Full Text] [Related]

  • 26. Localization of Unknown Primary Site with 68Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor.
    Menda Y, O'Dorisio TM, Howe JR, Schultz M, Dillon JS, Dick D, Watkins GL, Ginader T, Bushnell DL, Sunderland JJ, Zamba GKD, Graham M, O'Dorisio MS.
    J Nucl Med; 2017 Jul; 58(7):1054-1057. PubMed ID: 28153957
    [Abstract] [Full Text] [Related]

  • 27. Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study.
    Nicolas GP, Schreiter N, Kaul F, Uiters J, Bouterfa H, Kaufmann J, Erlanger TE, Cathomas R, Christ E, Fani M, Wild D.
    J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855
    [Abstract] [Full Text] [Related]

  • 28. [(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer.
    Tuncel M, Souvatzoglou M, Herrmann K, Stollfuss J, Schuster T, Weirich G, Wester HJ, Schwaiger M, Krause BJ.
    Nucl Med Biol; 2008 Aug; 35(6):689-95. PubMed ID: 18678354
    [Abstract] [Full Text] [Related]

  • 29. Intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy with (177)Lu- and (90)Y-DOTATOC (tandem PRRNT) in a patient with a metastatic neuroendocrine tumor.
    Todorović-Tirnanić M, Kaemmerer D, Prasad V, Hommann M, Baum RP.
    Recent Results Cancer Res; 2013 Aug; 194():487-96. PubMed ID: 22918778
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Early Dynamic 68Ga-DOTA-D-Phe1-Tyr3-Octreotide PET/CT in Patients With Hepatic Metastases of Neuroendocrine Tumors.
    Sänger PW, Freesmeyer M.
    Clin Nucl Med; 2016 Jun; 41(6):447-53. PubMed ID: 26859210
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors.
    Kowalski J, Henze M, Schuhmacher J, Mäcke HR, Hofmann M, Haberkorn U.
    Mol Imaging Biol; 2003 Jun; 5(1):42-8. PubMed ID: 14499161
    [Abstract] [Full Text] [Related]

  • 34. Iotandium-111 pentetreotide scintigraphy and CT scans after 3 years in the follow-up of patients with malignant melanoma.
    Zissimopoulos A, Karpouzis A, Kouskoukis C.
    Hell J Nucl Med; 2009 Jun; 12(2):142-5. PubMed ID: 19675868
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma.
    Tateishi U, Hosono A, Makimoto A, Nakamoto Y, Kaneta T, Fukuda H, Murakami K, Terauchi T, Suga T, Inoue T, Kim EE.
    Ann Nucl Med; 2009 Feb; 23(2):155-61. PubMed ID: 19225939
    [Abstract] [Full Text] [Related]

  • 37. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
    Etchebehere EC, de Oliveira Santos A, Gumz B, Vicente A, Hoff PG, Corradi G, Ichiki WA, de Almeida Filho JG, Cantoni S, Camargo EE, Costa FP.
    J Nucl Med; 2014 Oct; 55(10):1598-604. PubMed ID: 25168627
    [Abstract] [Full Text] [Related]

  • 38. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.
    Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schäfer M, Schilling T, Haufe S, Herrmann T, Haberkorn U.
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1617-26. PubMed ID: 17520251
    [Abstract] [Full Text] [Related]

  • 39. 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies.
    Paganelli G, Bodei L, Handkiewicz Junak D, Rocca P, Papi S, Lopera Sierra M, Gatti M, Chinol M, Bartolomei M, Fiorenza M, Grana C.
    Biopolymers; 2002 Oct; 66(6):393-8. PubMed ID: 12658726
    [Abstract] [Full Text] [Related]

  • 40. The role of positron emission tomography (PET) in diagnostics of gastroenteropancreatic neuroendocrine tumours (GEP NET).
    Junik R, Drobik P, Małkowski B, Kobus-Błachnio K.
    Adv Med Sci; 2006 Oct; 51():66-8. PubMed ID: 17357280
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 53.